CUPROUS Pharmaceuticals Inc. (CPI) is a Canadian biotech company that spun out from BC Cancer. The inspiration for CPI came from an interest in developing copper-activated drugs to treat aggressive cancers that are resistant to standard of care therapeutics. Metal complexes in general, exhibit therapeutic potential when used to treat a plethora of clinical conditions including, bacterial infections, inflammatory diseases, neurodegenerative diseases and cancers. Despite the therapeutic potential of metal complexes, there is a dearth of this class of drugs available for human use. The large gap between the chemistry creating these promising drug candidates and their pre-clinical and clinical development has been addressed through use of CPI’s platform Metaplex technology. Metaplex enables the development of pharmaceutically viable formulations of metal-binding small molecules. CPI is excited to co-develop best-in-class small molecule nanomedicines with partner industrial and academic/research institutions to address unmet medical needs.
THE CUPROUS TEAM
THOMAS REDELMEIER, PHD
Founder, CEO & President
MICHAEL ABRAMS, PHD
Vice President, Research
MARCEL BALLY, PHD
Founder, Chief Scientific Officer
ADA LEUNG, PHD
Founder, Director of Operations
We are looking for self-motivated talents to join our team. CPI embraces diversity and is an equal-opportunity employer.
BUSINESS DEVELOPMENT SPECIALIST